China Biologic Products (NASDAQ:CBPO) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Saturday.

Other equities research analysts have also recently issued research reports about the stock. ValuEngine raised shares of China Biologic Products from a “strong sell” rating to a “sell” rating in a research report on Monday, June 18th. Jefferies Financial Group cut shares of China Biologic Products from a “buy” rating to a “hold” rating in a research report on Monday, May 14th. Zacks Investment Research raised shares of China Biologic Products from a “sell” rating to a “hold” rating in a research report on Tuesday, July 17th. Finally, Credit Suisse Group cut shares of China Biologic Products from an “outperform” rating to a “neutral” rating in a report on Monday, August 6th. Two analysts have rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $101.00.

CBPO opened at $91.99 on Friday. China Biologic Products has a twelve month low of $71.85 and a twelve month high of $107.44. The stock has a market cap of $3.09 billion, a P/E ratio of 18.58, a PEG ratio of 1.69 and a beta of 1.36.

China Biologic Products (NASDAQ:CBPO) last posted its quarterly earnings data on Friday, August 3rd. The biopharmaceutical company reported $1.17 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.26 by ($0.09). China Biologic Products had a return on equity of 14.00% and a net margin of 15.89%. The firm had revenue of $120.40 million for the quarter, compared to the consensus estimate of $116.21 million. During the same period in the prior year, the company earned $1.35 EPS. The company’s revenue for the quarter was up 34.8% compared to the same quarter last year. analysts expect that China Biologic Products will post 4.25 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of the company. Jane Street Group LLC bought a new position in shares of China Biologic Products in the second quarter worth about $461,000. Point72 Hong Kong Ltd bought a new position in shares of China Biologic Products in the second quarter worth about $10,310,000. Point72 Asset Management L.P. bought a new position in shares of China Biologic Products in the second quarter worth about $1,281,000. Bank of America Corp DE lifted its holdings in shares of China Biologic Products by 19.8% in the second quarter. Bank of America Corp DE now owns 651,261 shares of the biopharmaceutical company’s stock worth $64,690,000 after acquiring an additional 107,573 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of China Biologic Products by 10.7% in the second quarter. Renaissance Technologies LLC now owns 123,600 shares of the biopharmaceutical company’s stock worth $12,277,000 after acquiring an additional 11,900 shares during the last quarter. 53.18% of the stock is owned by hedge funds and other institutional investors.

China Biologic Products Company Profile

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

Featured Article: Diversification Important in Investing

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.